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diseases and disabilities. Since their introduction in the 1940s, inactivated vaccines based on virus material grown in fertile hens' eggs have clearly been proven to be effective in decreasing mortality in these populations at risk whenever there is a sufficient match between the vaccine strain and the epidemic wild virus 1'2. The World Health Organization maintains a world-wide surveillance on influenza epidemiology and annually reviews the strain composition of the vaccine 3. Nowadays, highly purified vaccines without serious side-effects are available. Therefore, in many parts of the world, national and international health authorities recommend annual vaccine administration in subjects at risk for influenzaassociated complications. Despite the availability of influenza vaccines for half a century, uncertainty has existed for a long time about the standard vaccine dose. In the course of harmonization, doses have been standardized internationally. In the United States of America, vaccines containing 7.5/~g HA of each of the components until 1980; since then, the standard dose has been doubled to 15/~g HA. In most European countries, 10/,g HA has been used until 1991. From 1992 onwards, European influenza vaccines will also contain 15/*g HA per strain, according to the new European 'Harmonization of Requirements For Influenza Vaccines '4. Australian influenza vaccines also currently contain 15/~g HA per strain.
Apparently, the preference of health authorities for increased vaccine dosages is based on the established graded positive relationship between the vaccine dose and the resulting IgG antibody response in previously primed subjects s 7. Because high serum titres of IgG antibody against viral HA protect against infection with a homologous virus 8-11, the serological response of this antibody upon immunization has become the most useful surrogate marker of vaccine efficicy (regardless of the fact that, to various degrees, additional immunological factors, such as local antibody and cellular immunity, contribute to protection).
The arguments underlying the preference for the higher vaccine doses do not, however, address three important issues: first, the dose choice of pharmaceutical products should, in principle, be based on the concept of 'the lowest effective dose' and the benefit-risk ratio of the compound; second, vaccine production using fertilized hens' eggs is very laborious, involving a variety of logistical and environmental problems (risky dependency on a biological product, short time interval between the availability of annual vaccine strains and the beginning of the vaccination season); third, to counter the present, generally low, vaccination rates in high-risk patients, public campaigns are expected to increase the awareness of influenza and its prevention during the coming years. The expected increase in vaccine demand will put an enormous pressure on the current production capacity. The dependence on hens' eggs for vaccine production may then become a limiting factor.
In the light of these considerations, a standard dose of 15/~g HA or higher is justified only if an increase of vaccine dose from 10 to 15/~g HA has been shown, by scientific means, to be associated with a meaningful increase in the number of protected subjects. In this case, the three practical elements would be of lesser order.
From our own work 12 14, we doubted that an increase in vaccine dose from 10 to 15/~g HA would have an influence on the protection rate to such an extent that a decrease of available vaccine dosages is warranted. However, these vaccination trials may have suffered from a great variety of factors, such as prior experience of the study subjects with other influenza strains, state of health, or genetic conditions which may have superimposed a dose-effect in a single, limited study [15] [16] [17] . We therefore felt it necessary to review all available recent dose-response trials in the international scientific literature. We took into consideration the ongoing epidemiological situation where both influenza A (H3N2) and A (H1Nt) subtypes have been circulating for many years (since 1968 and 1978, respectively) and vaccination is usually offered to subjects already primed for these subtypes.
MATERIALS AND METHODS

Source of literature and selection of papers
The databases Biosis Previes (Philadelphia, PA, USA), Medline (National Library of Medicine, Bethesda, ML, USA), and Embase (Excerpta Medica, Amsterdam, The Netherlands) were searched for various combinations of the keywords 'influenza', 'vaccine' (vaccination), 'immunisation' (immunization) and 'dose' (doses, dosing, dosage, dosages) in papers written in English. The search was undertaken in January 1992 and covered the period January 1978 through December 1991.
Serological studies using the single-radial immunodiffusion (SRD) method to determine the antigen dose were selected for this review. The year 1978 was chosen for the following reason: since 1967, the antigenic contents of vaccines had been estimated by comparison with an international influenza A standard preparation and expressed in chick red blood cell agglutination (CCA) units. This method was not always reliable as it tended to underestimate vaccine contents when whole-virus particles were aggregated. Moreover, with the development of split and subunit vaccines, this technique Studies were selected in which at least two doses of an inactivated, aqueous influenza vaccine (whole-virus, WV; split, SPL; subunit, SU) without adjuvant were administered, in a randomized fashion, by the intramuscular or subcutaneous route. Any study design was accepted which included the sampling of two blood specimens (one before and a second after immunization), and the detection of IgG antibody against viral haemagglutinin by an appropriate assay. Tests measuring antibodies directed against other viral proteins (neuraminidase, M-protein) or measuring cellular immunity were excluded, in view of their unknown quantitative association with protection. Some studies include booster doses several weeks after the first immunization. In this review, data were selected from either the first or the second vaccination in view of the following: in subjects already primed for a given subtype, a booster vaccination will generally not increase antibody titres after the first vaccination with an influenza strain belonging to that same subtype. On the other hand, subjects not previously exposed to a given subtype (i.e. very young children, and defined age groups after first occurrence of pandemic strains), respond insufficiently to a first immunization and need a booster dose to reach an antibody level comparable to primed subjects. Obviously, in previously unprimed subjects, the first dose serves as primer which enables an adequate antibody production after booster dose 21-25. As we were interested in dose-response statements in primed populations, we selected data on first vaccination in primed subjects, and on booster vaccination in previously unprimed subjects.
Measures of serological response, and statistical analysis
In the selected publications which used the haemagglutination inhibition (HI) test or the indirect immunofluorescence (IIF) test, seroresponse was expressed by using one or more of the following measures: (1) the pre-and postvaccination geometric mean titres (GMT) and/or the difference between the logarithms of post-and pre-GMT (mean fold increase, MFI), (2) the protection rate (PR), i.e. the proportion of subjects exceeding a given protection threshold after vaccination, (3) the response rate (RR), i.e. the proportion of subjects showing at least a fourfold titre increase after vaccination. The data were taken directly from the selected papers, recalculated from their original data if given, or derived from appropriate original tables or figures. For calculation of the protection rate, a titre threshold of 408'16'24 was used, if not mentioned otherwise by the authors.
One paper in which a single radial haemolysis test is described 25 presented pre-and postvaccination antibody concentrations as haemolysis areas (in mm2), which were treated as GMT values in our analysis except for the logarithmation step. Post-GMT or MFI values could not be statistically analysed any further by us given the lack of original individual data. The significance level of differences between dose groups was taken from the original paper is given. PR and RR values were subjected to probit analysis z6 (PROBIT in SAS 6.06) as it is the procedure often practised in literature. However, this method has preconditions which may not be met by all studies. In order to use a uniformly well-fitting method for all studies, we also applied the linear k*2-Z 2 model 27 which has fewer preconditions on the data than probit analysis. With either method, protection and response rates were estimated for the 10 and 15/~g HA doses, as exemplified in Figure 1 .
The protection rate was supposed to be the most meaningful response measure. We assumed that an influenza vaccine should produce protection in at least 75% of primed but unprotected subjects, during the interpandemic period. (Table 1) The literature search for the period 1978 through 1991 produced 180 English-language papers. From these, the titles of 84 papers revealed that they dealt with subjects other than trials with inactivated influenza vaccines in humans, for example trials with experimental live vaccines, or trials in animals. The remaining 96 papers were read for the presence of dose-comparison data in primed populations, which were found in 32 papers. Of these, 12 papers were not included: two 2°'28 were, respectively, a summary and a part of a national trial which is described in three included papers29-31; one study (Ref. 32) described the same trial as Ref. 33 using a different serological technique; another 34 covers a selection of the study population which is described in the included paper35; one study 36 does not describe a previously planned trial with at-random allocation, but an accident during a mass vaccination campaign, and seven papers 37-43 used the obsolete CCA test to determine the vaccine dose. '56 did not take into account the influence of homologous prevaccination antibody titres on the seroresponse. In the other studies, this issue was addressed, although in different ways. Two papers described a prescreening of subjects for low pre-existing antibody titres before intake 12'a3. Five papers retrospectively stratified for prevaccination antibody 3°'44 47, two papers excluded all previously seropositive subjects a1'54, and two excluded retrospectively all subjects with high (protective) prevaccination titres ~ 2.5o. Two studies 52"53 included prevaccination titres in a statistical model and adjusted for this factor by regression analysis or analysis of covariance.
RESULTS
Papers reviewed
Seven papers 12'29'3°'45'47'51'52 gave information about the history of previous vaccination against influenza, but drew different consequences from that information; study designs varied considerably from exclusion of all previously vaccinated subjects 12 to inclusion of up to 74% 52 or 82% 29 of previously vaccinated subjects in the study samples.
All six studies performed in 1978 to test the new influenza A/USSR/77 (H1N1) strain addressed correctly the H1Nl-priming period by stratifying for age. Of the 14 remaining, more recent studies, five 12'33"46'47'54 addressed priming periods by a restricted prospective age selection of the participants, or by stratification for age. Measures of serological response. Table 1 presents also the measures of serological response which we could review. The pre-and postvaccination geometric mean titres (GMT), or measures derived from them, were the most common parameters to describe quantitatively the antibody response to the vaccine. Many papers also reported numbers, percentages or proportions of subjects under and beyond a threshold titre believed to correlate with protection. The threshold was a titre of 32-40 for those studies which used a test-antigen concentration of 4-8 HAU in the HI test, and higher (100 and 200, for influenza A and B, respectively) in the study which used 3 HAU 12. The indirect immunofluorescence assay used in Ref. 55 had a threshold of 2555. Numbers, percentages or rates expressing 'response' (titre rise of at least fourfold) were also often given. The paper in which the single radial haemolysis test was used 25, also presented response rates (based on the number of subjects within an increase of more than 45% between pre-and postvaccination haemolysis areas). Seven papers presented pre-or postimmunization titres in cumulative tables for discrete titre intervals 31,33,35,44.49,51,52.
Statistical analysis. The final column of Table 1 provides an indication of the statistical methods used to assess the significance of differences found between dose groups. No formal statistical analysis at all was applied in four studies 33'35'4s'49. In these studies, the absolute differences between groups were presented without addressing factors such as group size and probability calculations, i. Stratification groups, doses and serological data ( 56 Subjects were stratified, by the authors, according to various criteria. For this review, the groups for dose-comparisons were either adopted as reported in the original papers, or restratified as described in detail in Appendix 1. Data on different vaccine types were pooled by us where they showed no significant difference in antibody titres, according to the authors. Data on different influenza strains, however, were never pooled. Table 2 presents the results of this restratification procedure. Fifty stratification groups (SG) were derived from the 20 studies. SPL, WV and SU vaccines were used in 27, 22 and nine stratification groups, respectively (double scoring possible). Two papers 52'56 did not report the type of their vaccines. Many of the vaccine strains belonged to the influenza A-H1NI subtype (20 SG) with the A/USSR/92/77 virus as the most frequent single strain (nine SG); the remaining strains consisted of influenza B (16 SG) and A-H3N2 (14 SG) viruses.
The sample size of the stratification groups varied widely (between 29 and 1137 subjects). In bi-and trivalent vaccine studies, the same subjects are scored two or three times, separately for each strain. The total number of subjects in Table 2 (8921 subjects) is therefore considerably larger than the actual number of included subjects (7328 subjects). This assumes that after administration of bi-or trivalent vaccines, the antibody induction in any one subject is independent for each vaccine component. For further calculations, each stratification group is assumed to be a single, independent dose-response experiment.
The final column of Table 2 shows the vaccine doses tested for each of the 50 stratification groups, varying between 1.5 and 94/~g HA. Some stratification groups contain only two doses, others up to six. A complete list of available serological data for each dose of each stratification group, which was used for the collection of raw data for this review, is given in Appendix 2. (Table   3) . It was not possible for us to apply statistical procedures on pre-GMT, post-GMT, or MFI values. because no reference was made to within-group variances, and the original raw data were not available. Thus, the papers were checked for statistical calculations computed by the authors themselves. Table 3 presents those 39 stratification groups where the result of a statistical test on post-GMT or MFI had been reported by the authors. In column 'Result' of Table 3 , '+' indicates that the authors found a statistically significant difference between doses (~<0.05), and '-' means its absence. This descriptive review procedure revealed 11 significant stratification groups out of 39 (28%). There was no clear association between the result of the significance tests and the size of the stratification groups or the subtype/type of the vaccine strain (not shown). Very small total dose ranges (~<7/~g HA) showed no significant dose differences (SG 5, 20, (36) (37) (38) 43, 44) , but the other dose ranges did not correlate with the outcome; there were stratification groups with a large dose range which could not detect a significant dose-response relation (SG 10, 7-60/zg HA, SG 29 and SG 31, 15-60/~g HA). (Table 4) . Protection rates as reported in, or derived from, the reviewed papers, were subjected to statistical analysis, i.e. a weighted linear model based on the k*2-Z 2 test, and probit analysis. aPossibly not randomized 4-/ -, authors found/did not find a statistically significant difference between dose groups differences between inclusion criteria in the l0 and 15 #g HA. These doses had to be extrapolated with possibly doubtful validity. Table 4 also presents intercept and slope of the linear model. Interestingly, six out of 26 stratification groups (23%) showed a negative slope, and one a slope equal to zero. In these studies, higher vaccine doses were associated with lower or equal protection rates. Of the remaining ! 9 positive slopes, only three were significantly different from zero, thus showing a significant dose response relationship (SG 16, 19, 22) .
Dose comparisons
Dose comparisons of quantitative parameters
Dose comparisons of protection rates
Intercept and slope were used to estimate protection rates for l 0 and 15 #g HA doses. Despite the considerable differences between studies and the significance levels of the model parameters, these results were very consistent for influenza A: all four stratification groups with A-H3N2 vaccine strains, and nine from ten stratification groups with A-H 1N1 strain had protection rates greater than 75% at a dose of 10 #g HA. The median PR for all 14 influenza A strains was 81.5% with a range of 70 93%. For influenza B (9 SG), protection rates at 10 #g HA were more heterogeneous and generally lower than for the influenza A strains (range 51-97%, median 68%, six out of nine SG lower than 75%). This may reflect differences in laboratory techniques (some studies t2'5°'52'53 used ether-treated test antigen in the HI test, others did not), or in the definition of a protection threshold.
The estimated PR values at 15 #g HA were not much different from those at 10#g HA in non-immunecompromised populations. The difference between the protection rates varied between -3 and 6% in 22 out of 23 stratification groups with a median of 1%. The three stratification groups with a significantly positive slope did not differ from this pattern. Only SG 20, one of the stratification groups which should be interpreted cautiously, had a higher difference between the two doses (11%) but this may be meaningless, as this is the only stratification group with an extremely narrow dose range which makes extrapolation very unreliable (in the study, doses of 7 and 10 #g HA were compared). Moreover, the estimated (and real) PR value at 10 #g HA is already very high (91%), and the extrapolated PR value at 15 #g HA would exceed 100%. For the immune-compromised population represented in this review, patients on aPossibly not randomized bSIope significantly different from 0 to differences between inclusion criteria in the haemodialysis aS, the pattern appeared different. The PR values at 10/~g HA were, for all three vaccine components, very low (12-40%), and showed an increase of 6 8% at a dose of l5 #g HA.
Results yielded by probit analysis were similar to those of the linear model (last two columns of Table 4 ). Only one stratification group (SG 19) showed a major discrepancy between both methods (PR at 10/~g HA: 81% by linear model, and 94% by probit), obviously related to the fact that, of all stratification groups with only two doses, SG 19 had the largest dose range (7-60/~g HA). (Table 5) . Thirty stratification groups could be analysed for response rates (RR) ( Table 5 ). Both methods had insufficient model fitting in two cases (SG 25 and 33). In eight cases (SG 30, 33, 5, 20, 32, 35, 45, 46) , the doses did not include 10 and 15 #g HA. The estimations for intercept, slope, and RR values at doses of 10 and 15 #g HA were very similar for both methods. With the linear model, nine stratification groups (30%) had a negative slope; of the remaining 21 positive slopes, four were significantly different from zero (SG 26, 6, 22, 47) . Estimation of the RR at 10/~g HA, in non-immune-compromised populations, revealed a higher variability than for the protection rates, for all three virus subtypes/types (A-H3N2 34: 96%, median 85%; A-H1N1 39: 87%, median 76%; B 19: 98%, median 60%). Reasons for this variability may be related to the limitations of the response rate as a measure of seroresponse, and are addressed in the Discussion section of this review. Overall, the differences between RR values at doses of 10 and 15/~g HA varied between -9 and 8% in 26 out of 27 stratification groups, with a median of 1%. Again, SG 20 had a higher difference between the two doses (16%).
Dose comparisons of response rates
For patients on haemodialysis, the influenza B component (SG 47) showed the only huge increase, from an RR value of 20% at 10 #g HA to 41% at 15 #g HA.
DISCUSSION
Until recently, dose requirements for influenza vaccines in various countries were different from each other, which indicated a lack of consensus on the 'lowest effective dose', despite the great number of studies done to investigate this question. This may be related to the biological or experimental difficulties in establishing such a dose. The lowest effective dose may vary for different virus strains, different epidemiological situations, or different target groups, or may be dependent on the selected efficacy parameters to assess dose-effects. Dose-effects on the true efficacy parameters (influenza attack-rate, reduction in influenza-associated morbidity and mortality) can only be derived from field or challenge Table 4 studies, the latter being feasible only in healthy adults for ethical reasons. Hence, for practical reasons, the choice for the recommended vaccine doses has mainly been based on serological studies where homologous antibody titres are used as surrogate markers of efficacy. The 20 studies selected for this review covered doses from 1.5 to 94/~g HA. We found a fair amount of variation in study designs, study samples, priming and vaccination history of the vaccinees, group sizes, vaccine types, virus strains, laboratory techniques and statistical procedures for data analysis. We applied strict post hoc criteria to each study to form 50 stratification groups of subjects already primed for the vaccine strains, collected the data on seroresponse measures as given in the studies, and performed calculations to detect dose-effects within the stratification groups and to estimate the seroresponse at doses of 10 and 15 #g HA.
Quantitative seroresponse measures
There was a significant dose response relationship based on post-GMT or mean fold increase (MFI) values in 11 out of 39 stratification groups. Of course, detection of such a relationship is dependent on group size and the range of doses included in the experiment, but even after exclusion of seven stratification groups with a very small dose range (~<7/~g HA), the number of significant results appears small (11/32, 34%), particularly since some stratification groups with a very large dose range are included. This finding could suggest that a real relationship between antibody development after vaccination and vaccine dose does not exist at all, or is, at least, 'shallow '35. However, 34% with a significant result is far more than one would expect by chance in the absence of a real dose response relationship. More likely, in many studies other variables, insufficiently controlled, may have masked the dose-effect. The strongest determinant of postvaccination titre is the prevaccination (or baseline) titre 63"64 which was recognized and addressed in the majority of papers ( Table  1) but actually controlled only in two 52'53 where it was treated as a confounding factor in a statistical model.
Response rate
Another frequently used seroresponse measure in the papers reviewed was the RR used in 30 stratification groups (60%). Since RR is a dichotomous derivate of the MFI, it is also affected by the prevaccination antibody titre. In our opinion, this measure is mathematically inappropriate (even after statistically correcting for prevaccination titre), has no clear immunological or clinical implication, and should be avoided 14. Our theoretical considerations are confirmed by the large variability of the RR values when estimated for a dose of 10/~g HA (19 98%, Table 5 ). 900 Vaccine, Vol. 11, Issue 9, 1993
Protection rate
Clinically, the most meaningful seroresponse measure is the protection rate (PR). It is not strongly dependent on prevaccination titre as its calculation is based on subjects unprotected prior to vaccination (i.e. subjects with negative or low baseline). Therefore, this measure is also useful in studies which are insufficiently controlled for prevaccination titre. Indeed, the PR values estimated for a dose of 10/~g HA were much more consistent than the RR values. Virtually all stratification groups with influenza A had PR values equal to or higher than 75%. The papers consistently show that a dose of 10 #g HA of influenza A vaccine induces an antibody titre beyond the protection level in most primed and non-immunecompromised subjects.
For influenza B, the variation in PR values was larger (51-97%), and fewer stratification groups exceeded a PR of 75% (3/9, 33%). It may be assumed that influenza B antigens are less immunogenic than influenza A. However, the observed lower PR values may be related to artefacts of the laboratory techniques, especially the haemagglutination inhibition test which tends to produce low titres with influenza B antigens 65. Some authors ignored this problem, others addressed it by treating the antigen with ether to enhance its avidity, and again others by using a lower protection threshold than for influenza A antigens (for instance, 20 instead of 40). All this may have contributed to the higher variability of PR values for influenza B; the reason for some less favourable findings could therefore be of a technical nature.
Differences between PR and RR values for doses of 10 and 15/zg HA
Surprisingly, despite the limitations of the RR as a measure of seroresponse, and the PR in the case of influenza B, virtually no stratification groups for either RR or PR show a meaningful improvement when comparing their estimates for 10 and 15/~g HA. The stratification groups with a significantly positive slope show an increase of 2-6%, and the increases of other stratification groups oscillate around zero in a range from -9 to 8% (except SG 47). This is in good agreement with our own dose response study in 544 young and elderly subjects, vaccinated with doses of 0, 10, 20 and 60 ktg HA per strain 66. When treating the data by the same method as used in this review to interpolate PR values for 10 and 15/~g, we found the differences for three vaccine components and two age groups to vary between 1 and 3% only.
These results suggest that, at a dose level of 10 #g HA, the (sigmoid) dose-response curve has already passed the zone of its largest increase. An additional increase in the vaccine dose from 10 to 15 #g HA virtually does not improve the seroresponse as measured by protection or response rates. The expectation expressed in the European 'Harmonization of Requirements For Influenza Vaccines '4 that a vaccine dose of 15/~g HA per strain should be clinically superior to a dose of 10/~g HA per strain is not justified in vaccinees who are primed and have no manifest immunological disorders.
Immune-compromised subjects
One paper 55 dealt with a group of 51 patients on chronic intermittent haemodialysis with a manifest impairment of humoral immunity. There have been several unsuccessful attempts to overcome the low antibody production after influenza vaccination, for instance booster vaccinations some weeks later 67 or simultaneous administration of an immunomodulator 62. The results reported in Ref. 55 suggest that these patients might have benefited from a higher amount of antigen (for example, the simultaneous injection of two standard doses), and should stimulate more trials in this and similar immune-compromised groups.
Hoek, C.T., Janssen 
In the following comments on the 20 papers reviewed, numbers of pages, figures or tables mentioned refer to the original papers, unless italicized.
Nicholson et al. (Ref. 35)
The authors describe a complex vaccination trial in nine groups of volunteers with different age distributions and in different locations, using four different vaccine preparations containing the A/USSR/77 (H 1N 1) strain, two different modes of vaccine administration, and many dosages. After 1 month, the young age groups received a booster injection with the same vaccine and dosage as the first vaccination. Of the 1335 subjects entering the study, the authors themselves exclude one group of unknown size because of assumed occurrence of natural influenza in this group during the trial. Prevaccination HI antibody titres (as cumulative percentages) are presented for 980 subjects (Table 1) . On page 130 the authors state that they determined the HI antibody responses to vaccination for 972 subjects, but Tables 2-4 present only 938 subjects. No comment is given on the missing subjects. From Tables 2 4, the distribution of subjects shown in Table A1 can be derived.
Lavergne et aL (Ref. 44) Immunizations were performed in 667 healthy volunteers with two doses of a trivalent WV vaccine containing A/Texas/I/77 (H3N2), A/USSR/92/77 (H1N 1), and B/Hong Kong/2/73. Postvaccination sera of 77 subjects were not available. Serological data are presented for previously seronegative volunteers (Tables  IVa-c) and all volunteers (Tables Va-c) , stratified for three age groups (18 25, 26 50, 51-73 years of age). As the study population was regarded to be primed for influenza A (H3N2) and B, data of Tables Va and Vc were analysed in this review. For A/USSR/77, the data of age groups /> 26 years of age (primed), but not <26 (unprimed, no booster vaccination performed) were used here. In Table Vc , the total postvaccination GMT for the lower dose group is not 73 but 75. As no serological data on prevaccination sera were presented, no PR values could be analysed. Reasons for exclusion from this review: "The authors report that they had tested vaccine potency before delivering to and after returning from the study centres. The aqueous CTAB subunit vaccine lost all (low dosage) or much (high dosages) of its detectable HA contents, and data on antibody response were not reliable. For this review, those data are excluded ~The 29 young subjects receiving aqueous Triton SU vaccine are excluded because only one dosage (9/~g HA) was given in this group COnly aqueous, but not adjuvant vaccine preparations (in this case Al(OH)3-adsorbed ), are accepted for this review. The remaining 364 subjects form three different stratification groups ~According to our selection criteria, only subjects with subcutaneous or intramuscular vaccine administration are included
Brandriss et aL (Ref. 45)
These authors undertook a vaccination trial in 137 chronically ill, but not institutionalized, elderly, with monovalent or trivalent WV or SPL vaccines, in two dosages, and with booster vaccinations 3 weeks later. The authors did not present tables or figures showing the serological response on different doses, but only stated: '... when the subjects were combined according to dose (7/~g or 20/2g) ... the numbers were sufficient to suggest some significant differences in response. The postvaccination geometric mean titers to A/USSR/77 were higher after the 20 #g dose than after the 7 #g dose (I :144 versus 1:88.2, p<0.01) and were also higher to A/Texas/77 after 20 #g (1:87 versus 1:59.7, p<0.05). There were no significant differences between the 7-/~g and the 20-/~g preparations in the percentage of responders or the percentages of subjects with postvaccine HAI titers equal to or greater than 1:40.'
Quinnan et aL (Ref. 29)
A complex study is described which includes 517 subjects, with placebo (91 subjects) or monovalent and trivalent vaccine preparations from four manufacturers (WV and SPL), and booster injections for A/USSR/77 (H1N1) with the same vaccine preparation and dose as the first vaccinationl Numbers given in thetables donor always correlate with numbers in the text. There were no titre rises in the placebo subjects, suggesting absence of natural influenza during the performance of the trial. Data for the different vaccine preparations were pooled by the authors. Instead of the numerical vaccine dosages (7, 20, 60/~g HA), the real mean dosages as given in Tables 1 and 2 are used in this review. Table 1 (A/USSR/77) includes two age groups (16-25 years of age, unprimed, n = 132 subjects, and /> 26 years of age, primed, n= 185 subjects). Stratification has been done, by the authors, for previous vaccination with A/NJ/76 (Table 3) , but the numbers cannot be correlated to those in Table 1 . Therefore, this stratification is not included here. The authors found no major differences between subjects previously vaccinated and those not vaccinated 
Cate et al. (Ref. 30)
A study design was used similar to that described in Ref. 29 , with monovalent and trivalent vaccines from four manufacturers (WV and SPL), two (7, 20 #g HA) or three doses (7, 20 , 60#g HA), and booster injections for A/USSR/77 (H1N1) after 1 month, in two groups of volunteers (age range 20 33 years of age, n= 154, and 45 88 years of age, n= 138). On page 738, the age range of the first group is wrongly given as 20 23 . No information is given about the serology of the placebo groups. Unfortunately, data for 20 and 60 #g HA in the older adult age group vaccinated with A/USSR/77 (H1N1), were pooled by the authors as they found 'no major differences' between those dosages. These stratification groups had to be excluded as we were especially interested in those differences. Table 3 presents, according to priming periods, the immune response to A/USSR/77 (H1N1) only for 20 25-year-old and 55 88-year-old subjects. Table 4 gives the protection and response rates, but not the pre-and post-GMT-values, for all young and older subjects for all three antigens. This latter table was used for our review. Response rates, however, could not be used, as they were based on an unknown number of subjects with a prevaccination titre <~20. In total, 80 subjects could be included for the A/USSR/77 strain, and 218 subjects for A/Texas/77 and B/Hong Kong/72, respectively. We pooled the data for WV and SPL preparations. For A/Texas and B/Hong Kong, data for both age groups were pooled. Table A2 shows the comparison groups presented by the authors, and the pooling which has been made for this review.
Wright et al. (Ref. 31)
The authors use a study design similar to that in Ref. 29 with monovalent and trivalent SV and SPL vaccine preparations from four manufacturers, three dosages (2.3, 7, 20 #g HA), and booster injections for A/USSR/77 (H1N1). There were 358 children and 676 young adults (healthy and chronically ill, total 1034, of whom 235 received placebo). No information is given about random allocation of vaccine doses to subjects. Whether allocation was really done is doubtful, at least for the lowest dose, as the authors stated: 'It may also reflect the fact that the lowest vaccine dose (pediatric), which contained +2.3 pg of antigen, was selectively given to younger children .... '. Table 6 presents the antibody response to A/USSR/77 (H1N1) of initially seronegative subjects. For our review, data of different age classes (3 6, 7 12 and 13 25 years of age) and vaccine preparations were pooled to form a group of unprimed subjects. Of these, 355 received a booster dose; those data were included here. Table 7 presents the antibody responses to A/Texas/77 and B/Hong Kong/72 of initially seronegative subjects for the age classes 3 6, 7 12, and 13 25 years. The first age class was supposed to be unprimed, and its data were not included, as booster vaccination had not been done for those vaccine strains. The other two age classes, although seronegative prior to vaccination, were supposed to be primed, and their data were pooled and included here.
Gross et aL (Ref. 46)
This study was conducted in patients with cystic fibrosis (children, young adults), in part from St.
Vincent's Hospital, as was the case in Ref. 28 . It can be assumed that some in this study group also participated in that former study, but information about previous vaccination is not given. Two doses (7, 60/~g HA) of B/Singapore/79 are compared, given in a trivalent vaccine containing also 7 ktg HA/Bangkok/1/79 (H3N2) and 7#g A/Brazil/78 (H1N1). Dose groups were subdivided into subjects with negative and positive prevaccination titres for B/Singapore/79. The authors assume that previously seronegative subjects were unprimed for influenza B, which has been confirmed by a neutralization test. After 1 month most subjects in both dosage groups received a trivalent booster vaccine containing 7 #g HA of each strain. As this latter booster vaccination did not contain different dosages, only the data of the first vaccination in primed subjects were included in this review.
previously. Correction for prevaccination state is not discussed. The total number of volunteers is given as 148 in the text, but as 147 in Table 1 . The numbers for split/Chile groups and WV/Chile groups are obviously confused in Table 1 . The protection rates cannot be calculated because prevaccination data are not given. The authors report a significant difference in postvaccination GMT between groups split/Chile/15 #g and split/Chile/45 #g, but when calculating MFI values, this difference is smaller because the prevaccination GMT values differ in these groups. Whether actual MFI values differ significantly cannot be decided here. The 15 #g HA dose groups are compared with a group of children with cystic fibrosis and young adults (n=21); these data are not included here.
Beyer et aL (Ref. 12) Data are presented on healthy young students vaccinated with trivalent SPL vaccine, either 10 or 15 #g HA of each strain. The volumes of both doses differed per syringe (0.50 versus 0.75 ml), thus it can be assumed that the administration of vaccines was single-blinded but not double-blinded, as is stated in the text. Subjects were pretested for low prevaccination antibody titres. For calculations, subjects with high (protective) prevaccination antibody titres (influenza A > 100, influenza B, ether-treated > 200) were excluded. Absolute pre-and post-GMT values were recalculated from logarithm values. Table 4 also presents heterologous response to four other strains, and, as parameters, MFI and protection rates of responders only. These data were not included in this review.
Peters et aL (Ref. 52)
The authors describe a trial in elderly, some chronically ill, non-institutionalized subjects receiving trivalent vaccine (no information about vaccine type) each containing 15 #g HA of A/Philippines/82 (H3N2) and A/Chile/83 (HINI), and either 15#g B/USSR/83 (group I) or 60 #g B/USSR/83 (group III) into the right upper arm and, into the left upper arm, either placebo (group I and III) or 45 #g HA B/USSR/83 (group II). Numbers of subjects for pre-and first postvaccination sera: Group I, 42, group II, 44, group III, 45-2=43. The data of groups II and III, receiving a total amount of 60#g HA, have been pooled here. A second postvaccination sample (after 5 months) was drawn, but data are not presented here. Also, data about heterologous response were not included (they showed a difference between doses). The authors analysed the data by a regression model including age (not dependent), prevaccination state (dependent), and previous vaccinations (dependent). (H3N2) and A/Chile/83 (H1N1) of the second and the fourth group. The authors looked at the data on response and protection rates (~>32), but, unfortunately, did not present these data as they did not find significant differences between dose groups for any strain.
Subbotina et al. (ReL 54)
A mass vaccination trial is described in 2062 children and young adults (9 22 years of age) with a bivalent WV vaccine containing A/Kiev/59/79 (HINI) and A/ Leningrad/385/80 (H3N2). The vaccine doses were reported as 6 8 and 12 16#g HA; we used 7 and 14#g HA, respectively, for calculations. Whether a random allocation had been applied could be doubted considering the following statement: 'Vaccinations were conducted step by step starting with the oldest group to the youngest, first with a 6 8 #g HA dosage and then with the 12 16 #g HA dose'. Table 2 presents serological data for different age groups (pooled by us). The term 'seroconversion' is used but not defined by the authors: we supposed it to be an at least fourfold titre increase in subjects seronegative before vaccination. 
Guarnaccia et al (Ref. 56)
This study evaluated the practice of clinicians who diluted vaccine when immunizing subjects with allergy to egg proteins. In 29 healthy subjects (intake: 30), commercially available trivalent vaccine of unknown type was tested as original volume (0.5 ml), and as 1:5 and 1:10 dilutions. No information about contents in #g HA was given. Assuming 15 #g HA dose for the undiluted vaccine, as used in the United States at the time of performance of this study, the dosage groups would be 1.5, 3 and 15 #g HA. Little information on study design and no data about response or protection rates are provided. Pre-and 28-day-post-GMT-values are derived from Figures 1 3 according to GMT = exp(L*0.07 + 1.6), where L is the length of bar in mm. According to ANOVA done by authors, post-GMT of high and lower dosages differ significantly for the influenza A strains, but not for influenza B. However, pre-and postvaccination titres together formed the dependent variable of the analysis, while the dosage was an independent variable. Whether the differences between the MFI values for influenza A strains were also significant cannot be judged here. N1, size of dose group for calculation of GMT and PR; Pre GMT/Post GMT, absolute pre-/postvaccination geometric mean titre; MFI, Iogarithmated meanfold increase: log(Post GMT/Pre GMT); Pre prot/Post prot, number of subjects protected before/after vaccination; PR, protection rate: (Post prot-Pre prot)/(Nl-pre prot); N2, size of dose group for calculation of RR; Nresp, number of responders (subjects with >~4-fold titre rise); RR, response rate (Nresp/N2); -, missing value; ng, not given aPossibly not randomized 908 Vaccine, Vol. 11, Issue 9, 1993
